Our Story

HeartFlow is a medical technology company revolutionizing precision heart care.

There is no company in the world doing what we do—combining decades of human ingenuity and advanced technology in a completely novel way. We are passionate about transforming the diagnosis and management of coronary artery disease and continue to innovate, pushing into new frontiers and forging incredible partnerships along the way. Learn more about our story below.

Our History


Began development of image-based modeling for coronary blood flow

Charles Taylor PhD: expert in computational fluid dynamics at Stanford University

Christopher Zarins MD: chair of vascular surgery at Stanford University


Founded HeartFlow in Silicon Valley, California


Awarded CE Mark

Commercially available in Europe


Received U.S. FDA de novo 510(k) clearance

Commercially available in the U.S. (FFRCT First Generation)


Commercially available in Canada

Launched ADVANCE Registry to evaluate data from 5,000 patients


Commercially available in Japan

> 150 peer-reviewed publications
> 150 issued and allowed patents worldwide


NICE Guidance recommends HeartFlow

> 10,000 patients worldwide have received the HeartFlow Analysis


Innovation and Technology Payment Program Awarded by NHS England

Received reimbursement approval in Japan from MHLW

Launched PRECISE Randomized Clinical Trial

FFRCT 2nd Generation Released


Named one of the World’s Most Innovative Companies by Fast Company

FDA Clearance Received for HeartFlow Planner


FORECAST trial results show increased treatment efficiency with HeartFlow Analysis

JAMA Network Open Publication Demonstrates the Coronary CT-HeartFlow Analysis Pathway is ‘Dominant’ Compared to Stress Testing in Cost-Effectiveness Analysis

FFRCT officially recognized in the 2021 ACC/AHA Chest Pain Guidelines

>500 Peer reviewed publications supporting HeartFlow FFRCT


NHS England and NHS Improvement mandate adoption of AI-powered HeartFlow Analysis to fight coronary heart disease

Completes Patient Enrollment in the PRECISE Trial

FFRCT 3rd Generation Released



RoadMapTM FDA Clearance

Plaque FDA Clearance

Plaque New Tech APC Announced


FISH&CHIPS 2 Year Results

HeartFlow ONE Launched

FFRCT Transition to Category I Announced

250,000 Patients have received a HeartFlow FFRCT Analysis

While we continue to trailblaze in the field of cardiology, we are proud of our numerous accomplishments bringing us to where we are today, including more than 250,000 patients served, adoption at more than 750+ hospitals worldwide—including 80% of the Top 50 US Heart Hospitals—full coverage by Medicare and 96% of commercial lives in the United States, a robust body of clinical evidence including more than 500 peer-reviewed publications, and an IP portfolio of more than 400 issued and allowed patents worldwide. We are committed to continuing to transform the diagnosis and management of coronary artery disease and are grateful for the countless collaborations today and in the future to make this vision a reality worldwide.

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please use our online submission form on the Clinical Research Page to apply for research grants.

Thank you for your interest!

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.